4//SEC Filing
Decheng Capital China Life Sciences USD Fund III, L.P. 4
Accession 0001140361-21-033150
CIK 0001628945other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 5:48 PM ET
Size
9.3 KB
Accession
0001140361-21-033150
Insider Transaction Report
Form 4
Cue Health Inc.HLTH
Transactions
- Conversion
Common Stock
2021-09-28+8,192,468→ 8,192,468 total - Conversion
Series C-1 Preferred Stock
2021-09-28−8,192,468→ 0 total→ Common Stock (8,192,468 underlying)
Footnotes (2)
- [F1]On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
Cue Health Inc.
CIK 0001628945
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001736814
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 5:48 PM ET
- Size
- 9.3 KB